Plain-English translation of NCT06937112 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging medication called 18F-FAPI-YQ104 that uses a small amount of radioactivity to help doctors find tumors. The medication is designed to attach to cancer cells and light them up on a special scan, making it easier to spot lung cancer, pancreatic cancer, thyroid cancer, neuroendocrine tumors, and melanoma. Researchers want to make sure this treatment is safe and works better than current imaging methods.
Current imaging methods like CT and MRI scans don't always catch tumors early enough. This medication could help doctors spot cancers sooner and more accurately, potentially leading to better outcomes when caught at an earlier stage.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive an injection of the new radioactive medication and then undergo a specialized imaging scan to see how well it detects your tumor. The researchers will monitor your health and safety closely, checking your blood work and overall condition. The trial is based in China and involves about 20 patients total who have already been diagnosed with cancer.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Sponsor
Nanjing First Hospital, Nanjing Medical University
Enrollment target
~20 participants
Started
April 2025
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Feng Wang
Nanjing First Hospital, Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.